UBS Reiterates a 'Buy' on Johnson & Johnson (JNJ); Diving Into Valuation

August 1, 2012 12:10 PM EDT Send to a Friend
Get Alerts JNJ Hot Sheet
Price: $87.21 -1.41%

Rating Summary:
    8 Buy, 9 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 24 | New: 29
Trade JNJ Now!
UBS reiterates a 'Buy' on Johnson & Johnson (NYSE: JNJ) price target of $76.00 (from $70.00).

Analyst, Rajeev Jashnani, said, "Proabably the biggest point of contention that we hear on JNJ relates to valuation. While the stock does trade at 10% & 8% premiums to US large cap med tech & pharma groups, it is not clear to us that these broad averages are relevant comps. In med tech, JNJ has less exposure to sluggish cardio/ortho end-markets. In pharma, outlook vs. US peers is also fairly wide, as JNJ revs could grow at 6% over next 3 yrs vs. flattish for the broader group. JNJ trades at a ~30% discount to consumer.

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $69.22 yesterday, with a 52 week range of $59.08-$69.70.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change

Related Entities

UBS

Add Your Comment